Could a single injection fix early hip arthritis?
NCT ID NCT05276011
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an experimental injection called TG-C for people with early hip osteoarthritis. The injection contains cells that release a growth factor to help repair damaged cartilage. 255 adults will receive either TG-C or a placebo, and researchers will track pain and hip function for 12 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TG-C (TissueGene-C) – a single injection of cells that release a growth factor to help repair cartilage
- What this could lead to
- If it works, this could lead to a non-surgical treatment that reduces hip pain and delays or prevents the need for hip replacement.
- What could go wrong
- This is an early Phase 2 trial with only 255 people, so results may not apply to everyone. The injection is new and long-term safety is unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEGENERATIVE OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental bone putty for spinal surgery falls short in early trial
- New hip cup under observation: will it last?
- New hip implant under observation: will it stand the test of time?
- Could a single injection rebuild knees? phase 3 trial underway
- Could a single injection repair arthritic knees?
- Smart knee replacement: data platform aims to cut risks